This prospective observational study aims to investigate the impact of transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve edge-to-edge repair (M-TEER) on sleep-disordered breathing (SDB) in patients with significant valvular heart disease. Patients undergoing TAVI or M-TEER will be evaluated with full polysomnography prior to the intervention and at 6 months follow-up. Changes in sleep parameters, including apnea-hypopnea index (AHI), central and obstructive apnea indices, oxygen desaturation, and sleep architecture, will be assessed. In addition, the study will explore the association between changes in SDB and echocardiographic as well as arrhythmic parameters. The findings are expected to improve the understanding of the interaction between valvular heart disease and SDB and to identify potential benefits of transcatheter interventions on sleep-related outcomes.
Study Type
OBSERVATIONAL
Enrollment
150
Hippocratio General Hospital of Athens
Athens, Attica, Greece
RECRUITINGChange in AHI
Assessment of change in AHI from baseline to 6 months after transcatheter valve intervention, as measured by full polysomnography.
Time frame: Baseline and 6 months
Change in central apnea index (CAI)
Assessment of change in CAI from baseline to 6 months after transcatheter valve intervention, as measured by full polysomnography.
Time frame: Baseline and 6 months
Change in obstructive apnea index (OAI)
Assessment of change in OAI from baseline to 6 months after transcatheter valve intervention, as measured by full polysomnography.
Time frame: Baseline and 6 months
Change in oxygen desaturation index (ODI)
Assessment of change in ODI from baseline to 6 months after transcatheter valve intervention, as measured by full polysomnography.
Time frame: Baseline and 6 months
Change in Epworth Sleepiness Scale (ESS) score
Assessment of change in the ESS score from baseline to 6 months after transcatheter valve intervention. The ESS is a self-administered questionnaire measuring daytime sleepiness, with scores ranging from 0 to 24; higher scores indicate worse daytime sleepiness.
Time frame: Baseline and 6 months
Change in Pittsburgh Sleep Quality Index (PSQI) score
Assessment of change in the PSQI global score from baseline to 6 months after transcatheter valve intervention. The PSQI is a self-administered questionnaire assessing sleep quality, with scores ranging from 0 to 21; higher scores indicate worse sleep quality.
Time frame: Baseline and 6 months
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score
Assessment of change in the EQ-5D-5L index score from baseline to 6 months after transcatheter valve intervention. The EQ-5D-5L index score is a standardized measure of health-related quality of life derived from the five EQ-5D dimensions; higher scores indicate better health
Time frame: Baseline and 6 months
Change in EuroQol Visual Analogue Scale (EQ VAS) score
Assessment of change in the EQ VAS score from baseline to 6 months after transcatheter valve intervention. The EQ VAS records the patient's self-rated health on a scale from 0 to 100, where higher scores indicate better health status.
Time frame: Baseline and 6 months
Change in left ventricular ejection fraction (LVEF)
Evaluation of change in LVEF, as assessed by transthoracic echocardiography, from baseline to 3 months and 6 months after transcatheter valve intervention.
Time frame: Baseline, 3 months, and 6 months
Change in systolic pulmonary artery pressure
Evaluation of change in systolic pulmonary artery pressure, as assessed by transthoracic echocardiography, from baseline to 3 months and 6 months after transcatheter valve intervention.
Time frame: Baseline, 3 months, and 6 months
Occurrence of arrhythmic events
Assessment of arrhythmias using 24-hour Holter monitoring.
Time frame: Up to 6 months
Number of participants with all-cause hospitalization
Number of participants with at least one hospitalization during follow-up after transcatheter valve intervention.
Time frame: Up to 6 months
Number of participants with all-cause mortality
Number of participants who die from any cause during follow-up after transcatheter valve intervention.
Time frame: Up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.